BERLIN, May 7 (Reuters) - The main challenge to raising
production of COVID-19 vaccines is how to quickly and
effectively transfer technology, Germany's health minister said
Friday, reiterating Berlin's opposition to a U.S. proposal to
waive patent protection.
"The main issue is not patent protection but production
capacity," Jens Spahn told a news conference on Friday.
In a jab at the Biden administration, Spahn also said: "I
would be delighted if the United States shows the same
willingness to export vaccines that we in Germany do."
(Reporting by Douglas Busvine and Paul Carrel, editing by Riham
Alkousaa)
Astrazeneca (AZN)
